BRISTOL, PA – June 12, 2025 –BioVid Corporation, a leader in cognitive insights and strategic consulting for the life sciences industry, today announced the promotion of Peggy Hirtle to Chief Executive Officer, effective immediately. This appointment marks the culmination of a remarkable growth trajectory, during which time the company has more than doubled in size and significantly expanded its client base across pharmaceutical, biotech, and medical device sectors under Hirtle’s operational leadership.

The transition signifies a defining moment in BioVid’s 27-year evolution. Founding CEO Andrew Aprill will move to Executive Chairman. Hirtle, who has served as President since 2019, now takes the helm of a transformed organization operating at the critical intersection of science, strategy, and artificial intelligence.

 

Proven Track Record of Transformational Growth

Since joining BioVid in 2019, Hirtle has orchestrated a profound evolution, guiding the company from a respected boutique firm to an industry-leading consultancy. Under her operational leadership, BioVid has successfully tripled its workforce while meticulously preserving the intimate client relationships and scientific rigor that established its formidable reputation.

“Six years ago, we brought Peggy in with a clear mission: to scale BioVid’s impact without losing our soul,” said Aprill. “She’s exceeded every expectation. This isn’t just a succession plan; it’s the natural evolution of a partnership that has already transformed our industry and set new benchmarks.”

The numbers underscore this success. BioVid now proudly serves over 40 life sciences organizations globally, a significant increase from 12 when Hirtle first arrived. The company has strategically expanded its offerings from behavioral research into AI-powered insights, sophisticated communications strategy, and advanced analytics.

 

Innovation Leadership That Wins Industry Recognition

Hirtle’s strategic vision led to the creation of CIAIRA™, BioVid’s proprietary Cognitive Insight AI platform. Built over three years of sustained investment in artificial intelligence and machine learning, CIAIRA was never intended as a simple efficiency tool. It was purposefully designed to generate deeper insight by combining social and behavioral science with advanced computational intelligence. Recognized with the 2025 AI Excellence Award from the Business Intelligence Group, CIAIRA is reshaping how life sciences companies uncover meaning in physician behaviors, patient experiences, and market dynamics. Its output strengthens strategic decision-making and informs the development of tactics that align more closely with how people think, feel, and act.

Beyond technological innovation, Hirtle has significantly evolved BioVid’s service architecture. Under her vision, BioVid contemporized its product offerings. This made the company’s work more strategic and differentiated while remaining focused on delivering value to clients. The evolution is reflected in award-winning offerings like DemandDefender™ and Emotivate™, which have elevated industry expectations for insight delivery and emotional resonance in healthcare communications. Her vision and impactful work earned her recognition as a 2024 MM+M Woman of Distinction for healthcare innovation leadership.

 

Market-Driven Vision for Accelerated Growth

“The life sciences industry is at an inflection point, facing unprecedented scientific complexity, rapid regulatory evolution, and intense commercial pressure,” said Hirtle. “Companies today don’t just need more data. They require critical intelligence that directly drives smarter, faster decisions. That’s our unmatched market advantage, and as CEO, I am committed to widening it through strategic growth and innovation.”

Hirtle outlined three strategic priorities for her tenure: further expanding CIAIRA’s AI capabilities to unlock deeper insights, deepening collaborative partnerships with emerging biotech companies through tailored engagement models, and accelerating international growth through targeted market expansion.

 

Institutional Strength Meets Entrepreneurial Vision

This leadership transition reflects BioVid’s maturation from a founder-led startup to an institutionally robust consultancy. With a seasoned executive team, proven methodologies, and an impressive client roster that includes 10 of the top 15 pharmaceutical companies globally, BioVid enters its next chapter with momentum and confidence.

“Our clients don’t see us merely as vendors. They regard us as strategic thought partners,” Hirtle emphasized. “That invaluable trust is earned daily through uncompromising scientific rigor, acute commercial insight, and genuine, collaborative partnership. My core job as CEO is to scale that intimacy and dedication while continuously pushing the boundaries of what becomes possible when cognitive science and artificial intelligence work together.”

 

About BioVid Corporation

Founded in 1998, BioVid Corporation is a leading cognitive insights and strategic consulting firm exclusively serving the global life sciences industry. With talent across research, strategy, and technology disciplines, BioVid integrates behavioral science, AI-powered analytics, and commercial expertise to empower pharmaceutical, biotechnology, and medical device organizations to make faster, smarter, and more human-centered decisions. The company’s award-winning CIAIRA platform has transformed how life sciences companies understand markets, physicians, and patients.

 

Media Availability

Peggy Hirtle is available for interviews to discuss BioVid’s growth trajectory, AI innovation in life sciences consulting, and her vision for the company’s future.

To learn more about BioVid’s capabilities and client success stories, visit www.biovid.com.

PRESS CONTACT Sal Zerilli
BioVid Corporation
szerilli@biovid.com